Патогенез ВИЧ-инфекции: 25 лет открытий и загадок ... - Tb-hiv.ru

112 AIDS, ðóññêîå èçäàíèå, 2009, òîì 2, N¹ 2 J. Levy137. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8(R) T-cell responsesto different HIV proteins have discordant associations with viralload. Nat Med 2007; 13:46–53.138. Lieberman J. Tracking the killers: how should we measure CD8 Tcells in HIV infection? AIDS 2004; 18:1489–1493.139. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIVspecificT cells is associated with T-cell exhaustion and disease progression.Nature 2006; 443:350–354.140. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1expression on HIV-specific CD8 R T cells leads to reversible immunedysfunction. Nat Med 2006; 12:1198–1202.141. Price DA, Goulder PJR, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.Proc Natl Acad Sci U S A 1997; 94:1890–1895.142. Yang OO. Aiming for successful vaccine-induced HIV-1-specific cytotoxicT lymphocytes. AIDS 2008; 22:325–331.143. Kinter AL, Hennessey M, Bell A, et al. CD25(R)CD4(R) regulatoryT cells from the peripheral blood of asymptomatic HIV-infected individualsregulate CD4(R) and CD8(R) HIV-specific T cell immuneresponses in vitro and are associated with favorable clinical markersof disease status. J Exp Med 2004; 200:331–343.144. Chougnet CA, Shearer GM. Regulatory T cells (Treg) and HIV/AIDS:summaryof the September 7–8, 2006 Workshop. AIDS ResHum Retroviruses 2007; 23:945–952.145. Kornfeld C, Ploquin MJ, Pandrea I, et al. Antiinflammatory profilesduring primary SIV infection in African green monkeys are associatedwith protection against AIDS. J Clin Invest 2005; 115:1082–1091.146. Smith TR, Kumar V. Revival of CD8R Treg-mediated suppression.Trends Immunol 2008; 29:337–342.147. Shearer GM, Clerici M. Protective immunity against HIV infection: hasnature done the experiment for us? Immunol Today 1996; 17:21–24.148. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infectionin Caucasian individuals bearing mutant alleles of the CCR-5chemokine receptor gene. Nature 1996; 382:722–725.149. Kebba A, Kaleebu P, Serwanga J, et al. HIV type 1 antigen-responsiveCD4R T-lymphocytes in exposed yet HIV type 1 seronegative Ugandans.AIDS Res Hum Retroviruses 2004; 20:67–75.150. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposedseronegatives: have they repelled the virus? Curr Opin Immunol1995; 7:448–455.151. Scott-Algara D, Truong LX, Versmisse P, et al. Increased NK cellactivity in HIV-1 exposed but uninfected Vietnamese intravasculardrug users. J Immunol 2003; 171:5663–5667.152. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistanceto HIV-1 infection among African female sex workers is associatedwith inhibitory KIR in the absence of their HLA ligands. J Immunol2006; 177:6588–6592.153. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA fromHIV-1-exposed uninfected individuals inhibit HIV-1 transcytosisacross human epithelial cells. J Immunol 2000; 165:5170–5176.154. Miyazawa M, Lopalco L, Mazzotta F, et al. Factors modulating susceptibilityto HIV infection: the «immunological advantage» of HIVexposedseronegative individuals. AIDS 2009 (in press).155. Stranford S, Skurnick J, Louria D, et al. Lack of infection in HIV-exposedindividuals is associated with a strong CD8R cell noncytotoxicanti-HIV response. Proc Natl Acad Sci U S A 1999; 96:1030–1035.156. Burgener A, Boutilier J, Wachihi C, et al. Identification of differentiallyexpressed proteins in the cervical mucosa of HIV-1-resistantsex workers. J Proteome Res 2008; 7:4446–4454.157. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte proteaseinhibitor: a human saliva protein exhibiting anti-human immunodeficiencyvirus 1 activity in vitro. J Clin Invest 1995; 96:456–464.158. Levy JA. HIV research: a need to focus on the right target. Lancet1995; 345:1619–1621.159. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excisionusing an evolved recombinase. Science 2007; 316:1912–1915.160. Levy JA. What can be achieved with an HIV vaccine? Lancet 2001;357:223–224.161. Hoover EA, Mullins JI, Chu HJ, Wasmoen TL. Development and testingof an inactivated feline leukemia virus vaccine. Semin Vet MedSurg (Small Anim) 1995; 10:238–243.162. Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK. FIV vaccine developmentand its importance to veterinary and human medicine:a reviewFIV vaccine 2002 update and review. Vet Immunol Immunopathol2002; 90:113–132.163. van de Wijgert JH, Shattock RJ. Vaginal microbicides: moving aheadafter an unexpected setback. AIDS 2007; 21:2369–2376.164. Cohen MS, GayC, Kashuba AD, Blower S, Paxton L. Narrative review:antiretroviral therapy to prevent the sexual transmission ofHIV-1. Ann Intern Med 2007; 146:591–601.165. Levy JA, Ziegler J. Acquired immune deficiency syndrome (AIDS) isan opportunistic infection and Kaposi’s sarcoma results from secondaryimmune stimulation. Lancet 1983; ii:78–81.166. Mellor AL, Munn DH. IDO expression by dendritic cells: toleranceand tryptophan catabolism. Nat Rev Immunol 2004; 4:762–774.